🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 59935V107
- Market Cap
- Small Cap
- IPO
- 5/9/2019 · $15.00/share
Business: Milestone Pharmaceuticals Inc. headquartered in Montreal, Canada with a U.S. subsidiary in Charlotte, N.C., is a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. Etripamil is a novel, potent and short-acting calcium channel blocker designed by Milestone and being developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of PSVT as they occur.
Company Contact
- CEO
- Joseph Oliveto
- CFO
- Amit Hasija
- Headquarters
- 1111 Dr. Frederik-Philips Blvd., Suite 420, Montréal, Québec, Canada H4M 2X6
- Phone
- 514-336-0444
- Investor Relations
- David Pitts, Argot Partners · 212-600-1902 · ir@milestonepharma.com